Snapiri O, Rosenberg Danziger C, Shirman N, et al. - Via performing this study, researchers aim to raise awareness for potential adverse reactions linked with BNT162b2, which is approved for the vaccination of adolescents over 16 years of age. In this case series of patients diagnosed with perimyocarditis following vaccination, all patients were males 16–18 years old, of Jewish descent. The patients presented with chest pain that started 1–3 days after vaccination (mean, 2.1 days). Symptoms began following the 2nd dose in 6 of the 7 patients, and following the 1st dose in 1 patient. A time association between coronavirus disease 2019 vaccine and perimyocarditis has been noted in adolescents. All cases were mild, although the true impact of this cardiac injury will be revealed only with long-term follow-up. While there appeared an increase in the incidence of perimyocarditis during the vaccination campaign period, a more comprehensive data collection on a wider scale should be done.